Aaron N Hata Selected Research

Aaron N Hata Research Topics

Disease

51	Neoplasms (Cancer) 04/2024 - 07/2004
27	Lung Neoplasms (Lung Cancer) 03/2024 - 01/2013
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 06/2014
3	Residual Neoplasm 01/2022 - 01/2021
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 03/2015
3	Inflammation (Inflammations) 01/2019 - 08/2004
2	Genomic Instability 04/2024 - 08/2023
2	Melanoma (Melanoma, Malignant) 04/2024 - 07/2013
2	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 03/2023
2	Adenocarcinoma of Lung 01/2017 - 11/2016
1	Immunoglobulin Light-chain Amyloidosis 10/2022
1	Multiple Myeloma 10/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2021
1	Disease Progression 01/2021
1	COVID-19 01/2021
1	Small Cell Carcinoma 01/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019
1	Carcinogenesis 01/2019
1	Brain Neoplasms (Brain Tumor) 01/2017
1	Neuroblastoma 02/2016

Drug/Important Bio-Agent (IBA)

8	Tyrosine Kinase InhibitorsIBA 12/2022 - 09/2016
7	Proteins (Proteins, Gene)FDA Link 04/2024 - 06/2014
6	lorlatinibIBA 01/2022 - 01/2018
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2016
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 07/2013
5	Phosphotransferases (Kinase)IBA 01/2022 - 07/2013
4	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 11/2021
4	Immune Checkpoint InhibitorsIBA 03/2024 - 09/2016
4	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2018
4	CrizotinibIBA 01/2021 - 01/2017
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2018 - 01/2013
3	LigandsIBA 04/2024 - 11/2016
3	Transcription Factors (Transcription Factor)IBA 04/2024 - 11/2016
3	AntibodiesIBA 03/2024 - 01/2020
3	NAD (NADH)IBA 04/2023 - 01/2023
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2019
3	ProstaglandinsIBA 09/2005 - 07/2004
2	Circulating Tumor DNAIBA 11/2023 - 01/2018
2	venetoclaxIBA 10/2022 - 02/2016
2	entrectinibIBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 08/2020 - 01/2020
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 01/2017
2	navitoclaxIBA 01/2018 - 03/2015
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2014 - 07/2013
1	UracilIBA 04/2024
1	Cysteine (L-Cysteine)FDA Link 04/2024
1	CytidineIBA 04/2024
1	Cytidine DeaminaseIBA 08/2023
1	PlasticsIBA 06/2023
1	CollagenIBA 06/2023
1	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 04/2023
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2023
1	Eukaryotic Initiation Factor-4F (EIF4F)IBA 01/2023
1	MicroRNAs (MicroRNA)IBA 12/2022
1	Proteasome InhibitorsIBA 10/2022
1	Bortezomib (Velcade)FDA Link 10/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 10/2022
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2021
1	AntioxidantsIBA 01/2021
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	AlginatesIBA 01/2021
1	sotorasibIBA 01/2021
1	cabozantinibIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	adagrasibIBA 01/2021
1	capmatinibIBA 01/2021
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	AntigensIBA 01/2020
1	EpitopesIBA 01/2020
1	Small Nuclear RNA (snRNA)IBA 01/2020
1	Adenosine Triphosphatases (ATPase)IBA 01/2020
1	Small Cytoplasmic RNAIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	osimertinibIBA 01/2020
1	Metalloproteases (Metalloproteinases)IBA 01/2020
1	alectinibIBA 11/2019
1	Temozolomide (Temodar)FDA LinkGeneric 10/2019
1	olaparibIBA 10/2019
1	CytokinesIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019
1	Tyrosine (L-Tyrosine)FDA Link 01/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2019
1	Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA 12/2018
1	nazartinibIBA 01/2018
1	B7-H1 AntigenIBA 01/2017
1	Aurora Kinase AIBA 02/2016
1	MLN 8237IBA 02/2016
1	rociletinibIBA 07/2015
1	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 03/2015
1	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2014

Therapy/Procedure

33	Therapeutics 03/2024 - 01/2013
4	Drug Therapy (Chemotherapy) 12/2021 - 03/2016
3	Aftercare (After-Treatment) 01/2020 - 07/2013
1	Immunotherapy 01/2020
1	Radiotherapy 01/2019